Myriad Genetics (MYGN) Misses Q1 EPS by 2c; Maintains Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Myriad Genetics (MYGN) Misses Q1 EPS by 2c; Maintains Outlook

Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results

November 1, 2016 4:05 PM EDT

Total Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance

SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2017, provided an update on recent business highlights,  maintained its fiscal year 2017 financial guidance and issued fiscal second-quarter 2017 financial guidance. 

"We were pleased with the first quarter as our hereditary cancer business returned to more normal... More